Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01)
A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Sponsor: National Cancer Centre, Singapore
Terminated
The study had poor efficacy.
Other terminated trials from National Cancer Centre, Singapore
Other Epithelial Ovarian Cancer trials with similar outcome
A PHASE1/PHASE2 clinical study on Epithelial Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Centre, Singapore and has accumulated 9 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Jul 2022 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Unknown Status → Terminated
▶ Show 4 earlier versions
-
Oct 2020 — Dec 2020 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Oct 2018 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Centre, Singapore
For direct contact, visit the study record on ClinicalTrials.gov .